Therapy News and Research

RSS

Biogen Idec to join global MS community to commemorate the second annual World MS Day

On May 26, Biogen Idec will join the global multiple sclerosis community to commemorate the second annual World MS Day. Biogen Idec is a leader in the fight against MS, bringing hope to the thousands of patients across the globe who benefit from the company's MS therapies and ongoing research programs.

25 May 2010

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX®) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).

25 May 2010

Joint research by UB and CDC could lead to new generation of antiviral medicines

Future pandemics of seasonal flu, H1N1 and other drug-resistant viruses may be thwarted by a potent, immune-boosting payload that is effectively delivered to cells by gold nanorods, report scientists at the University at Buffalo and the U.S. Centers for Disease Control and Prevention. The work is published in the current issue of the Proceedings of the National Academy of Sciences.

25 May 2010

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented efficacy, safety and biodistribution results on its new biotherapy AMEP™ for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy in Washington, DC (May 17 - 22, 2010).

25 May 2010

Researchers explore impact of asymptomatic LV dysfunction in vascular surgery patients

Symptomatic heart failure prior to surgery is routinely acknowledged as a risk factor for adverse outcomes for both cardiac and non-cardiac surgeries. In a new study published in the June Anesthesiology, researchers delve further into the implications of cardiac problems on postoperative outcomes, exploring preoperative diagnosis and impact of asymptomatic left ventricular dysfunction in vascular surgery patients.

25 May 2010

Combination therapy improves patients with depression symptoms: Study

New data presented today at the American Psychiatric Association's annual meeting suggests a benefit to combining L-methylfolate, a prescription medical food called Deplin, with an antidepressant at the start of treatment. This retrospective analysis showed a significantly greater improvement in depression symptoms in a shorter period of time, when patients with Major Depressive Disorder were started on combination therapy.

25 May 2010

FDA approves Watson Pharmaceuticals' generic version of VALTREX tablets

Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application for Valacyclovir Hydrochloride tablets, USP, in the 500 and 1000 mg strengths, the generic equivalent to GlaxoSmithKline, LLC's VALTREX tablets.

25 May 2010

Advances in health IT

The New York Times: A "broad transformation in health care underway" is "fueled in good part by technology" that "promises to shift a lot of the diagnosis, monitoring and treatment of disease from hospitals and specialized clinics, where treatment is expensive, to primary care physicians and patients themselves — at far less cost."

25 May 2010

BinaxNOW PBP2a test to detect PBP2a in MRSA

AdvanDx today announced that it will offer the BinaxNOW PBP2a test from Inverness Medical Innovations, Inc. (Waltham, MA) to customers in the United States. The test provides rapid detection of the penicillin-binding protein 2a present in Methicillin-Resistant Staphylococcus aureus (MRSA) directly from S. aureus positive blood cultures.

24 May 2010

66% of patients with schizophrenia have extreme trust in their psychiatrists: New survey

According to a new survey sponsored by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, 80 percent of patients with schizophrenia, a chronic, severe and disabling brain disorder, say their psychiatrists do well or very well in treating them with courtesy and respect. This positive relationship is particularly important in treating schizophrenia as patients and psychiatrists must work closely together to determine appropriate treatment plans that will help patients manage their symptoms and reduce their risk of relapse.

24 May 2010

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Salix Pharmaceuticals, Ltd. today announced the availability of Xifaxan (rifaximin) 550 mg tablets for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. Those HE patients may now fill their Xifaxan 550 mg prescriptions in U.S. pharmacies and should speak with their doctors about this important treatment option.

24 May 2010

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Sangamo BioSciences, Inc. announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in fifteen presentations given by Sangamo scientists and collaborators at the 13th Annual Meeting of the American Society of Gene and Cell Therapy.

24 May 2010

2010 ASCO Annual Meeting highlights new research findings on cancer

Experts from The Cancer Institute at NYU Langone Medical Center will present new research findings at the 46th Annual Meeting of The American Society of Clinical Oncology (ASCO) in Chicago, Illinois.

24 May 2010

Volcano to highlight extensive pipeline of imaging and therapy products at EuroPCR 2010

Volcano Corporation announced today the company's plans to highlight its new product launches, presence in live cases, and participation in late breaking trials during EuroPCR from May 25 – 28 in Paris.

24 May 2010

New therapies can turn cancer into chronic disease

Two new studies suggest that the prolonged use of cancer drugs helped stunt the progress of the disease, a shift from the scheduled courses of treatment typically delivered to patients, The Wall Street Journal reports.

24 May 2010

South Dakota State University mathematicians design mathematical models to treat cancer

South Dakota State University mathematicians are helping doctors of the Mayo Clinic build mathematical models to fine-tune an innovative strategy to treat cancer.

24 May 2010

Researchers develop new therapy for psychological treatment of patients suffering from fibromyalgia

Researchers of the Labpsictec at the Universitat Jaume I of Castellon and the LahHuman Group at the Universidad Politecnica of Valencia and the University of Valencia have developed a new therapy based on the use of mobile devices and virtual reality for the psychological treatment of patients suffering from fibromyalgia.

24 May 2010

Poor survival rates in non-Hodgkin's lymphoma patients attributed to lifestyle factors

A new study led by researchers from Mayo Clinic in collaboration with six other U.S. institutions has found that patients with non-Hodgkin's lymphoma who smoked, consumed alcohol or were obese before their cancer diagnosis had poorer overall survival, compared to patients who did not have these risk factors.

24 May 2010

Young Faces of ALS campaign to raise awareness on ALS

The ALS Therapy Development Institute announced today that it is supporting a new awareness campaign driven by several ALS patients diagnosed with the progressive neurodegenerative disease commonly known as Lou Gehrig's disease before the age of 30. This campaign, called "Young Faces of ALS," is designed and led by a group of seven young men and women and will consist of a group effort to visit each of the 30 Major League Baseball parks during the 2010 baseball season.

21 May 2010

High family medical bills appear to reduce use of expensive medications: Study

People with rheumatoid arthritis whose health insurance requires them to pay a higher share of the cost are less likely to use biotech drugs than those with coverage that is more generous. High family medical bills also appear to reduce the use of these powerful but expensive medications, according to a new study in Health Services Research.

21 May 2010

Therapy News and Research

Biogen Idec to join global MS community to commemorate the second annual World MS Day

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Joint research by UB and CDC could lead to new generation of antiviral medicines

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

Researchers explore impact of asymptomatic LV dysfunction in vascular surgery patients

Combination therapy improves patients with depression symptoms: Study

FDA approves Watson Pharmaceuticals' generic version of VALTREX tablets

Advances in health IT

BinaxNOW PBP2a test to detect PBP2a in MRSA

66% of patients with schizophrenia have extreme trust in their psychiatrists: New survey

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

2010 ASCO Annual Meeting highlights new research findings on cancer

Volcano to highlight extensive pipeline of imaging and therapy products at EuroPCR 2010

New therapies can turn cancer into chronic disease

South Dakota State University mathematicians design mathematical models to treat cancer

Researchers develop new therapy for psychological treatment of patients suffering from fibromyalgia

Poor survival rates in non-Hodgkin's lymphoma patients attributed to lifestyle factors

Young Faces of ALS campaign to raise awareness on ALS

High family medical bills appear to reduce use of expensive medications: Study

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News